Italia markets closed

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,8800+0,0100 (+0,26%)
Alla chiusura: 04:00PM EDT
3,9800 +0,10 (+2,58%)
Dopo ore: 07:59PM EDT

Codexis, Inc.

200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100
https://www.codexis.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno248

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Stephen George Dilly MBBS, Ph.D.Pres, CEO & Director75kN/D1960
Mr. John J. NicolsDirector & Strategic Advisor1,33M5,18M1964
Mr. Sriram Ryali M.B.A.Chief Financial OfficerN/DN/D1982
Mr. Kevin Norrett M.B.A., M.S.Chief Operating OfficerN/DN/D1973
Ms. Margaret Fitzgerald J.D.Chief Legal and Compliance Officer, Gen. Counsel & Sec.N/DN/DN/D
Ms. Karen Frechou-ArmijoSr. VP & Head of HRN/DN/DN/D
Mr. Rob Wilson Ph.D.Sr. VP & GM of Performance EnzymesN/DN/DN/D
Dr. Karl A. Schoene Ph.D.Sr. VP of Devel. & OperationsN/DN/DN/D
Dr. Stefan Lutz Ph.D.Sr. VP of ResearchN/DN/DN/D
Mr. Robert Sato M.B.A., Ph.D.Sr. VP of Pharmaceutical Devel., Quality & RegulatoryN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Governance aziendale

L'ISS Governance QualityScore di Codexis, Inc. al 1 marzo 2023 è 5. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 7; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.